Tocilizumab in Systemic Sclerosis Interstitial Lung Disease: Safety and Efficacy in the Double-Blind and Open-Label Periods of a Randomized Controlled Phase 3 Trial
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.